Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
07:30am, Tuesday, 16'th Sep 2025
MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Tuesday, 02'nd Sep 2025
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for ne
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
04:05pm, Tuesday, 12'th Aug 2025
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neu
Annovis Completes Full Patent Transfer to Crystal Buntanetap
08:00am, Thursday, 07'th Aug 2025
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 pa
Annovis to Attend the AAIC 2025 with Four Poster Presentations
08:00am, Thursday, 26'th Jun 2025
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neu
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance
06:30am, Thursday, 19'th Jun 2025
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neu
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
01:00pm, Wednesday, 11'th Jun 2025
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Annovis to Host Webinar and Live Q&A on June 24, 2025
08:00am, Thursday, 05'th Jun 2025
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative dis
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results
04:30pm, Tuesday, 13'th May 2025
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neuro
Annovis Bio Appoints Hui Liu as Director of Biostatistics
08:00am, Tuesday, 29'th Apr 2025
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurode
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
04:30pm, Thursday, 27'th Mar 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
08:00am, Tuesday, 25'th Mar 2025
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseas
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
05:05pm, Friday, 21'st Mar 2025
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neu
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
08:00am, Tuesday, 11'th Mar 2025
MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseas
Annovis to Host Patients' Live Forum on February 27, 2025
08:30am, Wednesday, 19'th Feb 2025
MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurode
